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suffered from lipoatrophy for a comparatively small pe-
riod of time.  Conclusion: With the new recommenda-
tions to dilute PLA powder and to inject it into the deep-
er subcutaneous tissue nodule formation is a minor 
problem. However, good treatment results can only be 
achieved if lipoatrophy is not too intense; treatment in-
tervals should be about 2–3 weeks. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 In the past decade considerable progress was achieved 
in antiretroviral therapy by the combination of reverse 
transcriptase inhibitors and protease inhibitors. In many 
patients inhibition of HIV replication could be achieved, 
leading to an increase in CD4 cells, termed ‘immunore-
constitution’, and as a result reducing the incidence of 
opportunistic infections followed by prolonged survival 
 [1] . 
 In the context of this highly active antiretroviral ther-
apy (HAART), many patients developed the so-called li-
podystrophy syndrome, in particular if based on the use 
of stavudine and didanosine  [2–5] . The lipodystrophy 
syndrome is characterized by a fat distribution derange-
ment and metabolic changes. This is a multifactorial phe-
nomenon in which HIV infection, antiretroviral therapy, 
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 Abstract 
 Introduction: Facial lipoatrophy is a crucial problem of 
HIV-infected patients undergoing highly active antiretro-
viral therapy (HAART). Poly- L -lactic acid (PLA),  provided 
as New-Fill®/Sculptra™, is known as one possible treat-
ment option. In 2004 PLA was approved by the FDA as 
Sculptra™ for the treatment of lipoatrophy of the face in 
HIV-infected patients. While the fi rst trials demonstrated 
relevant effi cacy, this was to some extent linked to un-
wanted effects. As the depth of injection was considered 
relevant in this context, the application modalities of the 
preparation were changed. The preparation was to be 
injected more deeply into subcutaneous tissue, after in-
creased dilution.  Material and Methods: To test this ap-
proach we performed a pilot study following the new 
recommendations in 14 patients.  Results: While the ef-
fi cacy turned out to be about the same, tolerability was 
markedly improved. The increase in facial dermal thick-
ness was particularly obvious in those patients who had 
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as well as individual factors may play a role  [6] . The risk 
of developing lipodystrophy rises with duration of treat-
ment, patient age, degree of immunodefi ciency and in-
fl ammatory states  [7] . In vitro measurements have led to 
the hypothesis that nucleoside reverse transcriptase in-
hibitors (NRTI) inhibit the fatty acid proteins responsible 
for cellular fat uptake and intracellular fat transport. 
Treatment with protease inhibitors results in an extended 
turnover of free fatty acids with increased lipolysis and 
reduced clearance of VLDL triglycerides and chylomi-
crons. The toxic effect of NRTI on mitochondrial func-
tion is considered a major contributor to the lipodystro-
phy syndrome. Although adipocytes were not expected to 
be preferential targets of mitochondrial toxicity. A recent 
re-evaluation of the role of mitochondria in white adipo-
cytes might help explain the molecular basis of HAART-
associated lipodystrophy. Adipocytes are a source of 
paracrine and endocrine signals that infl uence the biology 
of adipocytes and systemic metabolism. Mitochondrial 
disturbances induced by HAART result in abnormal per-
ception of the bioenergetic status by adipocytes, leading 
to enhancement of catalytic pathways and apoptosis in 
peripheral adipose tissue, alterations in the differentia-
tion of brown versus white adipocytes, and the release of 
hormonal signals that lead to systemic metabolic distur-
bances  [8] . The exact pathogenesis of this type of lipoat-
rophy is still unclear  [5] . 
 Although there is no standardized defi nition of the 
HIV-associated lipodystrophy syndrome, it is usually 
classifi ed into three different forms: lipoatrophy, central 
adiposity, and a combination of lipoatrophy and central 
adiposity. In particular structural fat is involved. 
 Lipoatrophy is mainly characterized by a loss of sub-
cutaneous fat, especially in the face (nasolabial region, 
cheek, temples and eye sockets), the buttocks and extrem-
ities  [9] . The latter leading to an accentuation of the veins 
of the legs. Central adiposity is characterized by an in-
crease in the volume of the abdomen (crix belli), due to 
an accumulation of visceral fat, breast and nuchal fat de-
position (buffalo hump). Multiple lipomas of the extrem-
ities may also develop  [10, 11] . These side effects may 
lead to a decrease in compliance with the treatment. 
 These physical changes are often accompanied by 
complex metabolic changes, as hypertriglyceridemia, hy-
percholesterolemia, increased free fatty acids, lowered 
high density lipoprotein (HDL), glucose tolerance dis-
orders, diabetes and peripheral and hepatic insulin re-
sistance. A lipodystrophy syndrome is seen in 30–50% 
of patients receiving HAART therapy. The metabolic 
changes may enhance the cardiovascular risk  [12–15] . 
 Especially the fat loss on the cheeks and temples is 
typical for the illness and therefore stigmatizing the HIV-
infected patients which may lead to extensive psycho-
logical distress and social isolation. 
 In order to prevent the lipodystrophy syndrome, anti-
retroviral therapy should be changed as far as possible. 
Depending on the extent of the metabolic fi ndings, di-
etary measures should be considered and smoking should 
be stopped. In addition, patients should do some physical 
exercise and a treatment with medications that lower se-
rum lipids may be necessary  [4, 5, 16, 17] . 
 Poly- L -lactic acid (PLA) was recently approved in the 
USA as Sculptra TM  for the indication of lipoatrophy in 
HIV-infected patients who underwent antiretroviral ther-
apy  [18, 19] . In Europe, PLA had already been approved 
as New-Fill® in 1999 for soft tissue augmentation and 
correction of wrinkles in general  [20] . PLA, a member of 
the   -hydroxy acid group of compounds, is a synthetic 
biodegradable polymer  [21] . It is made of microparticles 
of 40–63   m and contains levo isomer lactic acid, poly-
merized to a macromolecule. New-Fill/Sculptra is hydro-
lyzed to water (H 2 O) and carbon dioxide (CO 2 ), which is 
eliminated by the lungs and kidneys. PLA increases total 
cutaneous thickness as shown in different studies on HIV 
patients who suffered from lipoatrophy during antiretro-
viral therapy  [21, 22] . The mechanism of the increase in 
tissue thickness is not yet known. Induction of collagen 
production is discussed, as well as an increase in the num-
bers of fi broblasts  [23] . Nodule formation is the main 
disadvantage of this therapy. PLA is known to induce a 
fi brovascular and macrophage cellular infi ltrate  [4] . While 
nodules seem to occur even more often in healthy – per-
haps in particular in atopic – individuals, they have also 
been noted in HIV-infected patients undergoing antiret-
roviral therapy  [25] . This reduced prevalence might re-
fl ect an altered immunocompetence. Based on the experi-
ence gathered both in HIV-infected and other patients, it 
was tempting to speculate that comparatively superfi cial 
injections and high concentrations conforming to previ-
ous package inserts might have been the main causes of 
this unwanted effect  [26, 27] . 
 Patients and Methods 
 Study Design 
 This study was an open label, uncontrolled pilot study to evalu-
ate the wanted and unwanted effects of PLA based on higher dilu-
tion and deeper injections in the context of facial lipoatrophy of 
HIV-infected patients following the recommendations of the new 
package insert  [28] . Patients over 18 years with a facial lipoatrophy 
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undergoing HAART were enrolled (n = 14). All patients gave writ-
ten informed consent to participate in the study. Before the fi rst 
treatment, the thickness of fat tissue in the right upper and lower 
buccal region of all patients was measured by 10-MHz sonography. 
The dermal thickness of the right upper and lower buccal region 
was assessed before each treatment and after a follow-up period of 
6 months. Pictures were taken before every injection, and after the 
follow-up period. 
 Preparation of PLA for Injection 
 Before injection, 150 mg dry sterile PLA powder taken from 1 
vial of New-Fill (Aventis Pharma Deutschland, Bad Soden, Ger-
many) was dissolved by addition of 4–5 ml of water for injection 
(Braun, Melsungen, Germany) and 1 ml local anesthetic (lidocaine; 
Prilocain®) using an 18-gauge needle (BD Microlance™  3, Becton-
Dickinson, Heidelberg, Germany) following the manufacturer’s 
current recommendations, as specifi ed in the package insert  [28] . 
The water for injections was added slowly and without inducing 
pressure. For 2 h the New-Fill preparation was not shaken. There-
after, the preparation was shaken using a vortexer (Mini Vortexer, 
Fisher Scientifi c, Springfi eld, N.J., USA, speed 10) until there were 
no more aggregates in the vial or later in the syringe. The local an-
esthetic was added immediately prior to injection. 
 Injection Technique 
 The patients were inspected fi rst in a sitting and then in a lying 
position. This approach was chosen as the lesions look different 
according to position. It was considered helpful to begin with the 
injections in the cheek region, because other areas of the face can 
lift up through treatment of the cheek region. The next region to 
treat was the nasolabial fold, the third the angle of the mouth and 
the last the chin. At each visit, patients received several injections 
into the deeper subcutaneous tissue of the atrophied area of both 
cheeks in a row using the tunneling technique after thorough dis-
infection. The tunneling technique is a technique in which a cavity 
is formed by inserting the needle to a 30- to 40-degree angle and 
then lowering the needle to inject parallel to the skin. This tunnel 
was fi lled with the preparation while retracting the needle. This was 
performed in a criss-cross or fan-shaped manner. The dermato-
logic surgeons tried to inject without pressure to prevent clogging 
in the syringe. The syringes were only fi lled with 0.7 ml, not 1.0 ml, 
in order to gain a better handling of the syringe. Each tunnel was 
only fi lled with 0.1 ml. The injected quantity at each visit depend-
ed on the actual fat loss in the area at the given point of time. No 
overcorrection was intended. The injections were performed every 
4–6 weeks, from 2 to 10 times according to severity. The injections 
were made with Luer Lok™ 1-ml syringes (Becton-Dickinson, Sin-
gapore, Singapore) and 26-gauge needles (BD Microlance™ 3, Bec-
ton-Dickinson). At each visit a maximum of 3–4 ml was injected. 
The injections were always performed by the same two trained der-
matologic surgeons. After the injections the cheeks of the patients 
were thoroughly massaged to avoid nodules. The patients were in-
structed to massage their cheeks both from the inside and the out-
side in the fi rst evening after cleansing of their hands. 
 Clinical Evaluation Including Sonographic Measurements 
 Sonographic evaluation (10 MHz) to quantify skin thickness 
was performed by the same two trained dermatologists using Toshi-
ba diagnostic ultrasound equipment (Toshiba, model SSA-340A, 
Tokyo, Japan) at the start and each follow-up visit including the 
one at 6 months after the last application. All ultrasound examina-
tions were recorded. To fi nd the exact region at follow-up visits, the 
crucial points were drawn on the patient’s face. The right distal 
buccal area served as the index area for comparisons, both on so-
nographic and clinical grounds. Clinical judgement was based on 
photographs taken before treatment, at the end of treatment and 6 
months later. Grading was as follows: deterioration –, no change =, 
improvement, slight +, moderate ++, marked +++. 
 Statistical Evaluation 
 Skin thickness data obtained before treatment, at the end of 
treatment and 6 months thereafter were subjected to explorative 
data analysis using the Wilcoxon test. 
 Results 
 Fourteen patients were enrolled and 12 patients (2 fe-
males and 10 males) completed the pilot study. Their ages 
ranged from 36 to 66 years; median age was 51.5 years. 
CD4 counts at start ranged from 186 to 900   l –1 . Patient 
14 dropped out of the study suffering from a one-sided 
paralysis of the facial nerve occurring several days after 
the fi rst treatment. The facial paralysis was considered 
not to be a result of the New-Fill  injection, but rather of 
a concomitant viral infection and resolved without spe-
cifi c therapy after a few weeks. 
 The number of injections varied from patient to pa-
tient, as the patients suffered from different amounts of 
fat loss on their cheeks. The injections continued until the 
aesthetic amelioration was satisfactory in the eyes of the 
patients and the doctors or until it was clear that further 
injections would not improve the situation. 
 An increase in skin thickness, as measured by sonog-
raphy, was observed in all patients (p = 0.001), as shown 
in  table 1 in more detail. In 5 patients thickness had near-
ly doubled, in 5 patients it had tripled ( fi g. 1–3 ), in 1 pa-
tient it had quadrupled and quintupled in 1 patient at the 
end of treatment. Two patients benefi ted from an in-
crease in skin thickness of about half the thickness mea-
sured initially. Within the follow-up period skin thickness 
tended to regress slightly again, but p was not signifi cant 
in this case (p = 0.072). Skin thickness was signifi cantly 
increased at the 6-month follow-up in all patients com-
pared with skin thickness before treatment (p = 0.003). 
 Judging from the photographs, marked improvement 
was found in 6 patients, while no amelioration was seen 
in 6 patients. In 2 patients, no follow-up pictures were 
available. Patients with severe and/or long-standing al-
terations tended to respond less well. All patients who did 
not respond to therapy were judged as having very severe 
facial lipoatrophy at the beginning of the study. 
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Table 1. Baseline characteristics and changes with therapy











1 M 38 5 1.7 4.5 4.6 = =
2 M 58 9 3.3 6.8 7.1 = =
3 M 61 7 1.9 6.8 6.9 +++ ++
4 M 44 7 2.9 5.8 5.5 ++ +++
5 M 62 6 2.2 5.9 4.6 = =
6 M 54 10 1.7 6.3 5.9 = =
7 F 43 5 3.6 5.3 5.0 +++ +++
8 M 51 8 1.9 8.9 8.4 ++ ++
9 M 52 9 2.3 4.0 NF = NF
10 M 37 7 2.3 7.1 6.8 +++ ++
11 F 34 4 2.6 6.1 5.2 ++ +++
12 M 42 3 4.3 5.6 NF ? NF
13 M 64 8 2.2 7.6 7.9 = =
14 M 57 2 1.6 3.0 NF NF NF
 Skin thickness was measured by ultrasound. Patients with excessive facial lipoatrophy = no change; + = slight 
improvement; ++ = moderate improvement; +++ = marked improvement; M = male; F = female; NF = no follow-
up; ? = no photograph to judge clinical improvement.
 Fig. 1. Facial lipoatrophy. Male patient, 
clinical picture before treatment. 
 Fig. 2. Facial lipoatrophy. Male patient, 
clinical picture at end of treatment with 
PLA. 
 Fig. 3. Facial lipoatrophy. Male patient, 
clinical picture at 6-month follow-up. 
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 The injections of New-Fill were well tolerated and no 
serious side-effects were seen during treatment and the 
follow-up period. In particular, no nodule formation was 
observed. One patient developed slight hyperpigmenta-
tion after excessive sun exposure.  It resolved without 
special therapy after 1 month. One patient developed 
fl ushing at the injection site, but he was known to suffer 
from rosacea grade I. 
 Discussion 
 The physiologically ideal tissue fi ller is autologous tis-
sue. In patients with signifi cant lipoatrophy, however, 
lack of donor tissue can preclude autologous fat transfer. 
Additionally, transferred fat is likely to be subsequently 
lost in the ongoing lipoatrophy process. Purifi ed bovine 
collagen dermal fi llers are widely used in cosmetic proce-
dures, but the effects usually decline after 6 months and 
up to 6% of patients develop localized hypersensitivity 
reactions. Other subcutaneous fi llers such as allogenous 
or synthetic fi llers require insertion, which can be com-
plicated by rejection, infection, palpability and lack of 
natural appearance with dynamic movement. In case of 
central adiposity, surgery or application of growth hor-
mones may be considered  [5, 16, 25, 29] . 
 The PLA polymer is supposed to induce collagen neo-
genesis, rather than a mechanical fi lling of defects. Tissue 
thickness may be enhanced by several millimeters to 
compensate fat loss. The possibility of developing granu-
lomas is known especially in cosmetic applications  [26, 
27, 29] . 
 In an open label pilot study (VEGA), the effi cacy and 
safety of PLA in HIV-infected patients with facial lipoat-
rophy was investigated. Fifty patients were included in 
the study; each of them received a total of 4 injections at 
intervals of 2 weeks. The follow-up period was 96 weeks. 
All patients had nearly complete loss of their cheek fat at 
the beginning of the study (thickness 0–2.1 mm). During 
therapy, median tissue thickness increased by 5.1 mm 
after 6 weeks, 6.4 mm at week 24 and 7.2 mm at weeks 
48 and 72. At week 96 (follow-up) median tissue thickness 
amounted to 6.8 mm (p  ! 0.001). In 22 of the treated pa-
tients palpable but not visible subcutaneous nodules ap-
peared. These nodules resolved spontaneously after 96 
weeks in only 6 patients  [21] . 
 To verify these data we performed a small study with 
14 patients receiving 5–9 injections of PLA at 4- to 6-
week intervals depending on their facial lipoatrophy. To 
avoid subcutaneous nodules, we chose a different recon-
stitution of the PLA powder with 4–5 ml water for injec-
tion and 1 ml local anesthetic  [19, 28] . In the VEGA 
study, in contrast, the PLA powder was reconstituted 
with 3–4 ml water for injection following the former rec-
ommendations  [21] . Besides the clinical assessment, we 
performed 10-MHz sonography and took photographs. 
 Tissue thickness doubled to quintupled in all our pa-
tients. The median total cutaneous thickness increased 
from baseline:  8 3.6 mm (range, 1.3–8.0 mm) before fi nal 
treatment and  8 3.9 mm (range, 1.4–7.5 mm) after 6 
months of follow-up. In all of our patients who completed 
the study we saw a signifi cant increase in facial dermal 
thickness. The increase was not absolutely stable in the 
follow-up period, but the decrease was not signifi cant. 
Aesthetic improvement could otherwise only be consid-
ered in half of the patients (6/12) who completed the 
study. Even in the patients where no clinical improve-
ment was seen, a measurable increase in tissue thickness 
was measured (double or triple thickness). All of these 
patients had a clinically pronounced lipoatrophy that was 
not improved after 5–10 treatment sessions. 
 In the VEGA study an increase of the median total 
cutaneous thickness was measured  8 6.4 mm at the end 
of therapy and  8 7.2 mm after a follow-up of 6 months 
 [21] . Moyle et al.  [22]  measured an increase of the me-
dian total cutaneous thickness of 4–5 mm 8 weeks after 
the fi nal injections only in the immediate-treatment 
group, not in the delayed-treatment group.  
 Moyle et al.  [22] demonstrated that an early therapy is 
signifi cantly more effective on a visual analogue score 
than delayed treatment. 
 These data are consistent with our fi ndings that early 
therapy with only little fat loss leads to better results than 
treatment in patients with extensive lipoatrophy. A prob-
able bias in our study may be the prolonged intervals be-
tween injections that may have led to less convincing clin-
ical results than described by Moyle et al.  [22] and Valan-
tin et al.  [21] . We think that the patients who clinically 
did not respond to therapy are patients with  severe facial 
fat loss; early treatment with New-Fill and shorter thera-
py intervals could have brought better results. 
 The effects of PLA have been shown to persist beyond 
2 years but they are not permanent and treatment may 
need to be repeated  [21] . 
 While effi cacy has not been a major subject of debate, 
safety has been considered an issue. In particular, nodule 
formation continues to infl uence the overall benefi t to 
risk ratio  [21, 27] . The present pilot study demonstrated 
that the current changes in the application mode of PLA 
do not compromise effi cacy; our less convincing results 
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compared with the VEGA study are related to the treat-
ment intervals, while the danger of nodule formation is 
virtually absent. Certainly, further large-scale trials will 
be needed to fi nd out to what extent this risk is really re-
duced and whether effi cacy is reduced as a result of the 
higher dilution of the PLA powder. For the time being it 
seems wise, in the patients’ interest, to follow the modi-
fi ed suggestions concerning the depth of injection and 
dilution of the active compound. 
 In Germany, the price for one vial of 150 mg PLA pow-
der is 175 EUR. The cost-benefi t ratio in our opinion is 
diffi cult to establish as the absence of a stigmatizing status 
of the HIV-infected patients receiving HAART cannot be 
quantifi ed. Since lipoatrophy is a part of HIV and its ther-
apy expenses should be covered by health insurance com-
panies allowing a number of treatment sessions, as most 
patients are improved the fi rst 5 injections. 
 Conclusion 
 With the new recommendations to dilute PLA powder 
and to inject it into the deeper subcutaneous tissue, nod-
ule formation is a minor problem. Since it is has been 
shown that the effect of PLA lasts for more than 2 years, 
it seems to be the most effective treatment of facial lipoat-
rophy in HIV-infected patients receiving HAART. Good 
treatment results can only be achieved if lipoatrophy is 
not too intense; treatment intervals should be about 2–3 
weeks. 
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